AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) is a healthcare company (biotechnology) based in Canada. The share price is $11.01, down 0.99% on the day, which values the company at $3.6B. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.
Key facts
- Share price
- $11.01−0.99% today
- Market value
- $3.6B
- Funk Score
- 28/100
- Against its own history
- Well above its usual priceusual price $5.99
- 200-week average
- $5.07117% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
AbCellera Biologics Inc. in more detail
ABCL trades at -15.6× next year's expected earnings, 54.3× sales. Measured against its own history, the price is 84% above what its usual multiples would imply ($5.99) — well above its usual price. It sits 117% above its 200-week average of $5.07.
Over the last five fiscal years AbCellera Biologics Inc. has compounded revenue -20.3% a year. Its Funk Score is 28 out of 100 (financial strength 8.3, profitability 0.9, growth 2.0, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Debt is growing faster than cash flow; Heavy stock-based pay.
1 of the superinvestors tracked here hold ABCL, including Julian and Felix Baker (1.3% of the portfolio).
Superinvestors holding ABCL
1 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors1.30% of portfolio · $259.1M · added · Q2 2026
AbCellera Biologics Inc. (ABCL): questions and answers
What is AbCellera Biologics Inc.'s market cap?
AbCellera Biologics Inc. is valued at $3.6B at a share price of $11.01.
Is ABCL overvalued or undervalued?
Against its own history, ABCL is well above its usual price: the price is 84% above the $5.99 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ABCL above its 200-week moving average?
Yes. ABCL is 117.3% above its 200-week average of $5.07. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is AbCellera Biologics Inc. growing?
Over the last five fiscal years AbCellera Biologics Inc.'s revenue grew -20.3% a year.
Does ABCL pay a dividend?
AbCellera Biologics Inc. does not currently pay a regular dividend.
Which famous investors own ABCL?
In their latest quarterly filings, Julian and Felix Baker (1.3% of the portfolio) hold ABCL. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “AbCellera Biologics Inc. (ABCL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ABCL
Underlying data: Yahoo Finance; company filings with the SEC.